KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Acquisitions & Divestments: 2011-2025

Historic Change in Acquisitions & Divestments for Jazz Pharmaceuticals (JAZZ) over the last 6 years, with Sep 2025 value amounting to $400.0 million.

  • Jazz Pharmaceuticals' Change in Acquisitions & Divestments rose 12.68% to $400.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 82.61%. This contributed to the annual value of $845.0 million for FY2024, which is 212.96% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Change in Acquisitions & Divestments stood at $400.0 million, which was down 14.89% from $470.0 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $760.0 million for Q1 2021, and its period low was $20.0 million during Q3 2023.
  • Its 3-year average for Change in Acquisitions & Divestments is $255.0 million, with a median of $290.0 million in 2024.
  • Data for Jazz Pharmaceuticals' Change in Acquisitions & Divestments shows a peak YoY skyrocketed of 1,675.00% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Change in Acquisitions & Divestments stood at $335.0 million in 2021, then reached $60.0 million in 2022, then spiked by 316.67% to $250.0 million in 2023, then grew by 16.00% to $290.0 million in 2024, then grew by 12.68% to $400.0 million in 2025.
  • Its last three reported values are $400.0 million in Q3 2025, $470.0 million for Q2 2025, and $310.0 million during Q1 2025.